TCGA-FD-A3B6-01A-21R-A20F-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 33.01576873
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.620
- MYC_TARGETS_V1+0.550
- E2F_TARGETS+0.530
- INTERFERON_ALPHA_RESPONSE+0.510
- ALLOGRAFT_REJECTION+0.500
- G2M_CHECKPOINT+0.480
- INTERFERON_GAMMA_RESPONSE+0.460
- UNFOLDED_PROTEIN_RESPONSE+0.430
- DNA_REPAIR+0.390
- MTORC1_SIGNALING+0.380
Top 10 suppressed
- BILE_ACID_METABOLISM-0.300
- KRAS_SIGNALING_DN-0.300
- MYOGENESIS-0.290
- CHOLESTEROL_HOMEOSTASIS-0.240
- NOTCH_SIGNALING-0.220
- WNT_BETA_CATENIN_SIGNALING-0.210
- HEDGEHOG_SIGNALING-0.170
- PANCREAS_BETA_CELLS-0.160
- APICAL_SURFACE-0.150
- ADIPOGENESIS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1210 | — | — | 0.902 |
| 2 | TCGA-BT-A3PJ-01A-21R-A220-07 | — | — | 0.893 |
| 3 | TCGA-52-7812-01A-11R-2125-07 | — | cohortA1 | 0.892 |
| 4 | TCGA-55-8205-01A-11R-2241-07 | — | cohortA1 | 0.884 |
| 5 | BS_4QW2S1Q8 | high-grade glioma | — | 0.879 |
| 6 | TCGA-PQ-A6FI-01A-11R-A31N-07 | — | — | 0.877 |
| 7 | SRR934927 | — | — | 0.877 |
| 8 | TCGA-GV-A40E-01A-12R-A23N-07 | — | — | 0.875 |
| 9 | C3N-00203 | — | cohortA1 | 0.874 |
| 10 | TCGA-G2-A2EF-01A-12R-A18C-07 | — | — | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.620 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.550 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.430 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.390 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.290 | Idelalisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.220 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |